Psoriasis: risankizumab tops adalimumab

  • Witjes H & al.
  • Clin Pharmacol Ther
  • 10 Sep 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Risankizumab is associated with superior efficacy compared with adalimumab for patients with moderate to severe psoriasis, according to a meta-analysis.

Why this matters

  • The meta-analysis supports results of a head-to-head trial (not included) demonstrating risankizumab superiority.

Key results

  • Risankizumab was associated with superior clinical efficacy compared with adalimumab after 16 weeks:
    • Estimated effect difference, 8.57% (95% CI, 5.59%-11.8%) for ≥50% improvement in the Psoriasis Area and Severity Index (PASI50).
    • Estimated effect difference, 15.2% (95% CI, 10.1%-20.4%) for PASI75.
    • Estimated effect difference, 23.7% (95% CI, 15.7%-31.2%) for PASI90.
    • Estimated effect difference, 20.8% (95% CI, 13.0%-28.7%) for PASI100.
    • Estimated effect difference, 20.1% (95% CI, 13.7%-26.1%) for a static Physician Global Assessment (sPGA) score of 0/1.
  • The effect differences were similar to those observed in the IMMvent head-to-head trial (13.5% for PASI50, 19.0% for PASI75, 25.1% for PASI90, 16.8% for PASI100, and 23.5% for sPGA 0/1).

Study design

  • 8 randomised controlled trials (3 for risankizumab and 5 for adalimumab) were included in the meta-analysis.
  • Funding: AbbVie.

Limitations

  • No analysis of long-term efficacy.
  • No safety comparison.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit